Journal profile · Neurosciences
Molecular Neurodegeneration
ISSN 1750-1326 · BioMed Central · ENGLAND · Monthly · Founded 2006
Molecular Neurodegeneration: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 19.56; fully open access; APC about USD 3,190; median 154 days to acceptance (97 articles, last 24 months); 130 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Molecular Neurodegeneration is published by BioMed Central and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Alzheimer's disease research and treatments, Neuroinflammation and Neurodegeneration Mechanisms and Parkinson's Disease Mechanisms and Treatments, together about 42.9% of its articles. Its main subfields are Neurology and Cellular and Molecular Neuroscience. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Neurodegeneration is an open access, peer-reviewed journal that encompasses all aspects of neurodegeneration research at the molecular and cellular levels. Neurodegenerative diseases collectively refer to neurological disorders that result from neurodegeneration and include, but are not limited to, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and glaucoma. These diseases, which are often associated with advanced aging and display varying degrees of dementia, have become a significant public health issue as humans live longer and the aging population grows larger. Recent advances in the molecular and cellular mechanisms underlying the pathogenesis of these neurodegenerative disorders have allowed for a better understanding of the disease mechanisms.
From the journal's Aims & Scope
Research area (LetPub): Neurosciences
Editor-in-chief Guojun BuPublisher website
Editorial board by country: 3 in mainland China (about 4%); most named United States 48, Mainland China 3, Belgium 3, Hong Kong, China 2, Germany 2 (67 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Alzheimer's disease research and treatmentsMedicine23.8%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience9.7%
- Parkinson's Disease Mechanisms and TreatmentsMedicine9.3%
- Amyotrophic Lateral Sclerosis ResearchMedicine8.1%
- Dementia and Cognitive Impairment ResearchMedicine6.4%
- Genetic Neurodegenerative DiseasesNeuroscience4.7%
- Neurogenesis and neuroplasticity mechanismsNeuroscience3.9%
- Nuclear Receptors and SignalingNeuroscience3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbasePsycINFOCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 19.56LetPub ·
- Impact factor (publisher) 2025
- 19.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 21.1Publisher website ·
- CiteScore 2026-06
- 25.1LetPub ·
- SJR 2026-06
- 6.26LetPub ·
- SNIP 2026-06
- 3.23LetPub ·
- h-index
- 66LetPub ·
- h-index
- 169OpenAlex ·
- i10-index
- 1,217OpenAlex ·
- 2-year mean citedness
- 18.44OpenAlex ·
- Self-citation rate
- 3.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 121LetPub ·
- Downloads per year (publisher) 2025
- 2,800,000Publisher website ·
Articles by year OpenAlex count · 1,611 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 78 | 78 | 77 |
| 2025 | 130 | 130 | 2,307 |
| 2024 | 100 | 100 | 3,295 |
| 2023 | 100 | 100 | 5,429 |
| 2022 | 85 | 85 | 6,906 |
| 2021 | 84 | 84 | 7,894 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
154 daysMedian, submission to acceptance · P25–P75 106 days – 201 days
- Acceptance to online
- median 16 days (97 articles)
- Submission to online
- median 176 days
- Sample
- 97 articles with submission and acceptance dates (239 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Submission to first decision
- 20 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,990 / USD 3,190 / GBP 2,590 | Yes | CC BY, CC0 | |
| OpenAlex | USD 3,090 / EUR 2,890 / GBP 2,490 | — | — | |
| LetPub | GBP 2,390 / USD 2,990 / EUR 2,790 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websitePolicy excerpts from the journal's websitePeer review
- Peer review
Collections may be peer reviewed by the journal's Editorial Board. Model summary
This collection has been peer reviewed by the journal's Editorial Board.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 2006
- ISSN
- 1750-1326
- Society / sponsor
- BrightFocus Foundation
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Molecular Neurodegeneration
What CAS zone is Molecular Neurodegeneration in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Neurodegeneration is in Zone 1 of Medicine, and in Zone 1 of the minor category Neurosciences; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Neurodegeneration?
The latest impact factor listed by LetPub is 19.56; CiteScore 25.1, h-index 169.
How long does peer review take at Molecular Neurodegeneration?
Based on the dates recorded on 97 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 154 days (interquartile range 106–201 days); authors report an average review time of 6–12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Molecular Neurodegeneration based?
Of the 67 board members whose country the journal's board page names, 3 (about 4%) are in mainland China; the countries named most often are United States (48), Mainland China (3) and Belgium (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Molecular Neurodegeneration?
According to LetPub and DOAJ records, Molecular Neurodegeneration is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase, PsycINFO and CAS; that list has not been checked against each database.
Is Molecular Neurodegeneration open access, and what is the APC?
Molecular Neurodegeneration is a fully open-access journal. APC about USD 3,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .